LCT.ASX
Living Cell Technologies to head pre-clinical studies of AI-116 cannabinoid to treat dementia
Living Cell Technologies (ASX: LCT) has entered into a research agreement with Melbourne’s La Trobe University for a range of pre-clinical studies assessing the effect of cannabinoid-based combination drug AI-116 on patients with dementia. The studies will employ state-of-the-art experimental techniques which are expected to provide valuable insights into AI-116’s mechanism of action by comparing […]
Market wrap: ASX falls as Bank of Japan flexes its muscles
The Australian share market shed 0.7% in Friday trade as the Bank of Japan shook up markets with a pledge to be more flexible in managing interest rates. The 52.3-point fall to 7403.6 points on the ASX 200 was a solid fall but still left the Australian market up 1.2% for the week after it […]
LCT makes headway on drug candidate pipeline for major disease treatments
Melbourne-headquartered biotechnology company Living Cell Technologies (ASX: LCT) made significant strides in its efforts to create a pharmaceutical company with a diversified product candidate pipeline during a busy June quarter. Boosted by a successful entitlement offer, LCT enters the second half of the year with a reported cash balance of $4.1 million at 30 June. […]
Living Cell Technologies files patent application over combination drug to treat dementia
Living Cell Technologies (ASX: LCT) has filed a provisional patent application over combination drug candidate AI-116 which contains cannabidiol (CBD) and an off-patent pharmaceutical ingredient for use in the treatment of dementia. The application establishes the priority date of the invention ahead of potential competitor companies and marks the start of a second research and […]